The Dalmia Centre for Research and Development (DCRD), R&D entity of Dalmia Group after years of extensive research, manufactured a polyherbal combination of 15 herbs called Astha-15, also mentioned in the Indian System of Medicine.

The study comes in the back of the Ministry of AYUSH last month recommending the use of herbal products like tea, spices, to overcome the pandemic. The polyherbal combination Astha-15, made available by the Group on March 16, has previously undergone a randomised double-blind, placebo-controlled study on patients, in speciality Government Hospital, Chennai, India. As per the double-blind study, the drug acts as a bronchodilator, decongestant, anti-inflammatory, lung detoxifier and didn’t show any side-effects. Now this polyherbal combination Astha-15 will undergo a phase III clinical trial with the most primary COVID-19 sites across India under the supervision of highly skilled physicians. This phase III clinical trial has been registered on CTRI with reg. no. CTRI/2020/06/025590.

"We are conducting human trials of our highly efficient ayurvedic composition which can potentially help in curing COVID-19 patients," Dalmia Group of Companies Chairman Sanjay Dalmia said.
Source: expresspharma.in, economictimes.indiatimes.com